This inventor holds 1 USPTO granted patent. Top assignees: Alexion Pharmaceuticals, Inc., National Institute of Health and Medical Research. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2026
Title: Soraya Sin-monnot: Innovator in Ciliopathy Treatment
Introduction
Soraya Sin-monnot is a prominent inventor based in Levallois-Perret, France. She has made significant contributions to the field of medicine, particularly in the treatment of diseases associated with ciliopathies. Her innovative approaches have the potential to improve the lives of many individuals affected by these conditions.
Latest Patents
Soraya holds a patent for "Methods for treating diseases associated with ciliopathies." This patent discloses methods of treating a ciliopathy-associated disease by administering an effective amount of a compound that targets at least one G-protein coupled receptor. Additionally, her patent outlines methods for identifying therapeutic agents for treating diseases related to ciliopathies. This includes providing an animal model system for testing potential therapeutic agents and comparing the measurable phenotypes of treated and untreated animals to identify effective treatments.
Career Highlights
Throughout her career, Soraya has worked with notable organizations such as Alexion Pharmaceuticals and the National Institute of Health and Medical Research. Her experience in these institutions has allowed her to develop her expertise in the field of medical research and innovation.
Collaborations
Soraya has collaborated with several professionals in her field, including Sophie Saunier and Luis Briseno-Roa. These collaborations have contributed to her research and the advancement of her patented methods.
Conclusion
Soraya Sin-monnot is a dedicated inventor whose work in treating ciliopathy-associated diseases showcases her commitment to medical innovation. Her contributions are paving the way for new therapeutic approaches that could significantly impact patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile